MDWD — MediWound Ltd.

Nasdaq · Materials · Chemicals · CIK 1593984 ·
Last close
$13.00
Market Cap
$167.83M
52W High
$16.86
52W Low
$12.86
ADV30
67,115
Next earnings
2026-08-13
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 1,475,000 323,000 -7,980,000 -2,952,000 79,982,000 38,559,000
Dec 2025 1,867,000 278,000 -7,813,000 -7,183,000 86,255,000 4,799,000 42,623,000
Sep 2025 5,429,000 896,000 -6,525,000 -2,652,000 94,423,000 44,267,000
Jun 2025 5,708,000 1,342,000 -5,716,000 -13,318,000 67,001,000 46,882,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-18,765,000
Investing CF
$3,149,000
Financing CF
$29,561,000
CapEx
$-6,366,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.26
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-228,925,000
Inventory
$4,772,000
Receivables
$2,748,000
ST Investments
$48,341,000
EBIT TTM
$-26,085,000
Pretax Income TTM
$-25,958,000
Interest Exp TTM
$7,564,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$11,863,000
EBITDA
$-30,749,000
Free Cash Flow
$-29,048,876
Enterprise Value
$141,097,616
Total Cash
$35,341,000
Total Debt
$8,605,000
Shares Out
12,910,278
Trailing EPS
$-2.16
Book Value
$2.76
ROE
-72.4%
ROA
-28.6%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 16,959,000 -25,279,000 -23,879,000 86,255,000 42,623,000 -16,121,000
Dec 2024 20,222,000 -19,382,000 -30,224,000 73,496,000 42,343,000 -13,624,000
Dec 2023 18,686,000 -15,501,000 -6,716,000 66,459,000 34,864,000 -10,465,000
Dec 2022 26,496,000 -7,661,000 -19,599,000 50,016,000 39,102,000 -11,885,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-2.29

Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $16.00 · spot: $13.06 · call volume: 63 · put volume: 97

Peers — same industry

TickerNameMarket CapLastDaily %
WALD Waldencast plc $157.26M $1.33
ZHJD Intelligent Hotel Group Ltd. $180.49M $1.78
CDXS CODEXIS, INC. $181.78M $1.66
SAFX XCF Global, Inc. $150.56M $0.37
YSG Yatsen Holding Ltd $191.33M $3.00

News headlines (Yahoo Finance, 1h cache)

MediWound (MDWD) Q2 2026 Earnings Call Transcript
2026-08-20 12:42 · Yahoo
MediWound Ltd (MDWD) (Q2 2026) Earnings Call Highlights: Record NexoBrid Sales and EscharEx ...
2026-08-13 23:07 · Yahoo
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-13 11:00 · Yahoo
MediWound to Report Second Quarter 2026 Financial Results
2026-07-29 12:00 · Yahoo
Will MediWound (NASDAQ:MDWD) Spend Its Cash Wisely?
2026-05-28 12:53 · Yahoo
MediWound Ltd (MDWD) Q1 2026 Earnings Call Highlights: Strategic Collaborations and Revenue ...
2026-05-27 21:00 · Yahoo
MediWound (MDWD) Q1 2026 Earnings Transcript
2026-05-27 18:34 · Yahoo
MediWound Q1 Earnings Call Highlights
2026-05-27 14:06 · Yahoo
MediWound to Report First Quarter 2026 Financial Results
2026-05-07 12:00 · Yahoo
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
2026-04-07 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.